Tandem Diabetes Care (TNDM) revenue breakdown
By product, Supplies and other is the largest at 54% of fiscal 2025 revenue, growing 14% a year over 3 years.
By region, United States is the largest at 70% of fiscal 2025 revenue; International grew fastest, 64% a year over 7 years.
Revenue by product
Fiscal years, as Tandem Diabetes Care reports them in its 10-K filings; fiscal 2025 total $1.0B.
| Products | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| Supplies and other | $373M | $407M | $476M | $551M | 54% |
| Pump | $432M | $366M | $434M | $464M | 46% |
| Net sales recognized (deferred) for Tandem Choice program | -$4M | -$25M | $30M | — | — |
Revenue by region
Fiscal years, as Tandem Diabetes Care reports them in its 10-K filings; fiscal 2025 total $1.0B.
| Regions | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| United States | $174M | $302M | $416M | $525M | $589M | $555M | $673M | $707M | 70% |
| International | $10M | $60M | $83M | $178M | $212M | $193M | $268M | $308M | 30% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TNDM.
Open TNDM in InvestinglyQuestions
Where does Tandem Diabetes Care make its money?
In fiscal 2025, by product: Supplies and other $551M, Pump $464M.
From Tandem Diabetes Care's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.